Thus, in level 2 we will assess the benefit of the different, AG014699 strategies (switch or augment) and will compare the benefit of individual treatment options within and between these strategies. Those with a satisfactory response will be followed naturalistically for 12 months. Those who do not have a satisfactory response will enter level 3. In level 3,

we compare 2 switch options (mirtazapine or nortriptyline) and 2 augment options (T3 and lithium). Those who remit will be followed and those remaining Inhibitors,research,lifescience,medical will enter level 4 in which we compare 2 additional switch options: tranylcypromine and the combination of mirtazapine and venlafaxine. The design is summarized in reference 59 and is reproduced in Figure 1. Figure 1. STAR*D (Sequenced Inhibitors,research,lifescience,medical Treatment Alternatives to Relieve Depression) algorithm.59Reproduced

from reference 59: Rush AJ, Trivedi M, Fava M. Depression IV: STAR*D treatment trial for depression, [images Inhibitors,research,lifescience,medical in Neuroscience]. Am J Psychiatry- 2003;1 60:237. Copyright … Details of the design and rationale have been published elsewhere58; basically the study is being carried out in 12 sites throughout, the USA. Each site serves as the hub for as many as 4 clinics with both primary care practices and specialty practices represented. The first patient Inhibitors,research,lifescience,medical enrolled in STAR*D in July 2001 and so the results will not be available

for several years. Conclusions Treatment-resistance is highly prevalent in depression; it is costly and is associated with extensive use of depression-related and general medical services. It poses unique therapeutic challenges and dilemmas in its management. Inhibitors,research,lifescience,medical Early identification and the use of effective long-term maintenance strategies are important. Decisions regarding treatment, including Cilengitide increase in dosage, antidepressant augmentation, switching to a different class of antidepressants, combination strategies, or other biological treatments and psychotherapeutic treatments should be made appropriately in the course of illness. Although no definite algorithm exists for treating resistant depression, research in this area has advanced considerably in recent years. This has the potential to enhance our understanding about the diagnostic and therapeutic aspects of TRD, to substantially reduce disability in this condition, and to enhance the quality of life of individuals with this condition.